I am opposed to this proposed change.  I understand there is some evidence that cannibas has value in certain disease states/cases.  I think changing the schedule will put an undue burden on physicians, pharmacists and supply chain to ensure that the correct patients meet the need & have access to the correct product.  Once all the evidence is published showing the real value of this drug and the supply chain issues are addressed, then look at changing the schedule.